Private Eye

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Off-market insider net buying at Eupraxia Pharmaceuticals (T:EPRX)

Updated Wednesday May 04, 2022 05:15 AM EDT

Llc Manchester Management Company, a 10% Holder, acquired 122,927 Common Shares on an indirect ownership basis for registered holder Jeb Partners L.P. and 2,511,122 Common Shares on an indirect ownership basis for registered holder Manchester Explorer, L.P. at a price of $2.050 through a private transaction on April 20th, 2022. The insider also acquired 122,927 Warrants on an indirect ownership basis for registered holder Jeb Partners L.P. and 2,511,122 Warrants on an indirect ownership basis for registered holder Manchester Explorer, L.P. with an exercise price of $3.000 for 48 moths. This represents a $5,399,800 net investment into the company's shares and an account share holdings change of greater than 100%.

Eupraxia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its lead product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). EP-104IAR contains a solid core of the active ingredient Fluticasone Propionate (FP) with an outer layer of the biocompatible polymer, PVA. In addition to EP-104IAR, the Company is also developing a pipeline of earlier-stage long-acting formulations. It develops pipeline candidates for a range of indications, such as post-surgical pain (EP-105), and post-surgical site infections (EP-201). The Company has completed a phase I, double-blind, placebo-controlled clinical study at three sites in Canada.

INK Edge Outlook

6 months ago
1 year ago
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Eupraxia Pharmaceuticals Inc. (EPRX)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $EPRX.CA

  • No tweets found